Dengue Virus IgM Serotyping by ELISA with Recombinant Mutant Envelope Proteins
Alexandra Rockstroh, Luisa Barzon, Widuranga Kumbukgolla, Hoang Xuan Su, Erley Lizarazo, Maria Fernanda Vincenti-Gonzalez, Adriana Tami, Alice M.M. Ornelas, Renato Santana Aguiar, Daniel Cadar, Jonas Schmidt-Chanasit, and Sebastian Ulbert
Author affiliations: Fraunhofer Institute for Cell Therapy and Immunology, Leipzig, Germany (A. Rockstroh, S. Ulbert); University of Padova, Padova, Italy (L. Barzon); Rajarata University of Sri Lanka, Mihinthale, Sri Lanka (W. Kumbukgolla); Vietnam Military Medical University, Hanoi, Vietnam (H.X. Su); University Medical Center Groningen, Groningen, the Netherlands (E. Lizarazo, M.F. Vincenti-Gonzalez, A. Tami); Federal University of Rio de Janeiro, Rio de Janeiro, Brazil (A.M.M. Ornelas, R.S. Aguiar); Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany (D. Cadar, J. Schmidt-Chanasit); German Centre for Infection Research, Hamburg (J. Schmidt-Chanasit)
Figure 1. DENV IgM ELISA titers, by serotype, for DENV PCR–positive serum samples from travelers returning to Germany or Italy, 2013–2016. A) DENV-1; B) DENV-2; C) DENV-3; D) DENV-4. Data lines indicate average titers; error bars indicate SDs. The antigens in this ELISA were Equad proteins (i.e., envelope protein from each DENV serotype with 4 amino acid changes T76R, Q77E, W101R, and L107R). In these examples, the highest endpoint titers corresponded to the DENV serotype identified by PCR analysis. DENV, dengue virus.
Page created: December 18, 2018
Page updated: December 18, 2018
Page reviewed: December 18, 2018
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.